



# Monte Carlo calculation of RBE and in-vitro validation for helium ion-beam therapy

MCMA 2017, Napoli

**Stewart “Mac” Mein**

*PhD Student*

German Cancer Research Center (DKFZ)


Translational Radiation Oncology Group — Dr. Amir Abdollahi

Heidelberg Ion-beam Therapy Center (HIT)


Biophysics in Particle Therapy Group — Dr. Andrea Mairani



- ◆ Comprehensive dosimetric characterization @ HIT
- ◆ Validation of Monte Carlo Tx Planning (MCTP) platform
- ◆ Preliminary plan comparisons (p. vs. He)





Meningioma cases (He)



physical + biological

## model surviving fraction (SF)



$$SF = e^{-(\alpha D + \beta D^2)}$$

$$RBE_{SF} = \frac{D_{SF}^X}{D_{SF}^P}$$

RBE(Dose, LET,  $[\alpha/\beta]$ ph)


## Methods:

### 1) Biophysical models (Theoretical)

- **MKM** = Microdosimetric Kinetic Model
- **LEM** = Local Effect Model

### 2) Phenomenological (Experimental)

- “Data-driven”
- Interpretation of collected data from the literature



● proton ● heavy ions

## FLUKA-coupled $D_{\text{bio}}$ Calculation



1999

Physical and biophysical characteristics of a fully modulated 72 MeV therapeutic proton beam: model predictions and experimental data

M. Biaggi <sup>a</sup>, F. Ballarini <sup>a,b</sup>, W. Burkard <sup>c</sup>, E. Egger <sup>c</sup>, A. Ferrari <sup>b,d</sup>, A. Ottolenghi <sup>a,b,\*</sup>



2010

**The FLUKA Monte Carlo code coupled with the local effect model for biological calculations in carbon ion therapy**

A Mairani <sup>1,2,6</sup>, S Brons <sup>2</sup>, F Cerutti <sup>3</sup>, A Fassò <sup>4</sup>, A Ferrari <sup>3</sup>, M Krämer <sup>5</sup>, K Parodi <sup>2</sup>, M Scholz <sup>5</sup> and F Sommerer <sup>3,7</sup>



2016

**Data-driven RBE parameterization for helium ion beams**

A Mairani <sup>1,2</sup>, G Magro <sup>1,3,4</sup>, I Dokic <sup>2,5,6,7</sup>, S M Valle <sup>3</sup>, T Tessonier <sup>7,8</sup>, R Galm <sup>2,5,6,7</sup>, M Ciocca <sup>1</sup>, K Parodi <sup>2,7,8</sup>, A Ferrari <sup>9</sup>, O Jäkel <sup>2,6</sup>, T Haberer <sup>2</sup>, P Pedroni <sup>4</sup> and T T Böhlen <sup>10</sup>

**Optimizing the modified microdosimetric kinetic model input parameters for proton and <sup>4</sup>He ion beam therapy application**

A Mairani <sup>1,2</sup>, G Magro <sup>1</sup>, T Tessonier <sup>3,4</sup>, T T Böhlen <sup>5</sup>, S Molinelli <sup>1</sup>, A Ferrari <sup>6</sup>, K Parodi <sup>2,3,4</sup>, J Debus <sup>2,3</sup> and T Haberer <sup>2</sup>




## 2016a Data-driven RBE parameterization for helium ion beams

## 2016b Biologically optimized helium ion plans: calculation approach and its *in vitro* validation

1.

### parameterization




A Mairani<sup>1,2</sup>, G Magro<sup>1,3,4</sup>, I Dokic<sup>2,5,6,7</sup>, S M Valle<sup>3</sup>, T Tessonnier<sup>7,8</sup>, R Galm<sup>2,5,6,7</sup>, M Ciocca<sup>1</sup>, K Parodi<sup>2,7,8</sup>, A Ferrari<sup>9</sup>, O Jäkel<sup>2,6</sup>, T Haberer<sup>2</sup>, P Pedroni<sup>4</sup> and T T Böhlen<sup>10</sup>

A Mairani<sup>1,2</sup>, I Dokic<sup>2,3,4,5</sup>, G Magro<sup>1</sup>, T Tessonnier<sup>5,6</sup>, F Kamp<sup>7</sup>, D J Carlson<sup>8</sup>, M Ciocca<sup>1</sup>, F Cerutti<sup>9</sup>, P R Sala<sup>10</sup>, A Ferrari<sup>9</sup>, T T Böhlen<sup>11</sup>, O Jäkel<sup>2,4</sup>, K Parodi<sup>2,5,6</sup>, J Debus<sup>2,5</sup>, A Abdollahi<sup>2,3,4,5</sup> and T Haberer<sup>2</sup>

### 2. Experimental validation

**Table 1.**  $\alpha_{\text{ph}}$  and  $\beta_{\text{ph}}$  values obtained by fitting the clonogenic A549 cell survival data with the linear-quadratic model are reported together with their uncertainties (one standard deviation, Mairani *et al* (2016) and Dokic *et al* (2016)).

Cell line	$\alpha_{\text{ph}}$ [Gy $^{-1}$ ]	$\beta_{\text{ph}}$ [Gy $^{-2}$ ]
A549	$0.173 \pm 0.026$	$0.032 \pm 0.004$



### 3. Model Comparisons

**Table 3.** Summary of the mean survival absolute predictions and experimental data.

RBE model	$\mu_{\Delta S}$ (%)
$f_{\text{QE}} + \beta_{\text{He}}(L)$	$9.8 \pm 1.3$
RBE = 1.3	$18.8 \pm 4.3$
LEM $D_t = 10.8$ Gy	$4.5 \pm 0.8$
LEM $D_t = 15$ Gy	$6.7 \pm 1.5$
RMF	$5.8 \pm 1.1$
New $f_{\text{LE2}} + \beta_{\text{He}}(L)$	$5.3 \pm 0.9$
New $f_{\text{LE2}} + \beta_{\text{He}} = \beta_{\text{ph}}$	$6.5 \pm 0.9$
LET $_D$ -based	$4.5 \pm 0.8$



2017

RBE models in 4-He ion beam therapy: predictions in clinically-relevant scenarios

↓ LET



↑ LET

↓  $(\alpha/\beta)_\gamma$



clinical  
relevance

↑  $(\alpha/\beta)_\gamma$



$$\text{RBE}(\text{Dose}, \text{LET}, [\alpha/\beta]_{ph})$$

## Clonogenic Assay with Pristine Peaks: RenCa cell-line

- Photon: [1 to 8 Gy]
- Determination of alpha ( $\alpha_{ph}$ ) and beta ( $\beta_{ph}$ )
- $^4\text{He}$  beam delivery: [0.25 to 3.3 Gy]
- $E_{\text{He}} = 56.65 \text{ MeV/u}$ , BP depth = 24 mm
- Biol. measurements: 6 and 21mm
- FLUKA simulations:  $D_{\text{eff}}$  [DD, MKM, LEM-IV]





FIG 1: Clonogenic assay post-irradiation imaging with the Incucyte™ demonstrating enhanced cell kill with increased dLET.







FIG 2 : Surviving Fraction (SF), RBE and local percent difference in RBE ( $\% \Delta RBE$ ) between predictions and experimental data.



## High-throughput Clonogenic Assay — Clinical-like Fields (SOBPs)


96 well plate approach (as in Guan et al 2015)






## High-throughput Clonogenic Assay — Clinical-like Fields (SOBPs)

H1460 cell-line

$$\alpha_{ph}/\beta_{ph} = 5.8$$



✓ Validity of 96-well plate high-throughput approach




## Validation of clinical TPS



**F**ast **R**ecalculation  
& **O**ptimization on **G**PU

- **In-house** development
- **Fast** performance (~minutes)
- **Excellent** agreement with Monte Carlo
- **GPU-based** dose calculation
  - with **ray tracing** [1]
  - and **pencil beam splitting** [2,3]
  - HIT physics database [p, He, C, O]
    - Monte Carlo Calculated



Validation against FLUKA — SOBPs in water

[1] Siddon, Prism representation: a 3D ray-tracing algorithm for radiotherapy applications, (1985)






[2] Kanematsu et al. Dynamic splitting of Gaussian pencil beams in heterogeneity-correction algorithms, (2009).

[3] Russo et al. A novel algorithm for the calculation of physical and biological irradiation quantities in scanned ion beam therapy: the beamlet superposition approach, (2016)



## Meningioma cases (He)



Dose [Gy]



- PTV
- Brainstem
- Chiasma
- Temporal Lobe (L)
- Temporal Lobe (R)

— FLUKA — FROG [PHYS]

..... FLUKA ..... FROG [BIO]



optimized via MCTP





## **German Cancer Research Center (DKFZ)**

*Translational Radiation Oncology Group*

Dr. Amir Abdollahi

Dr. Ivana Dokic

Carmen Klein

## **Heidelberg Ion-beam Therapy Center (HIT)**

Dr. Stephan Brons

Benjamin Ackerman

Dr. Thomas Haberer

## **CNAO**

Kyungdon Choi

Dr. Giuseppe Magro

## **Heidelberg University Clinic**

Dr. Jurgen Debus

*Biophysics in Particle Therapy Group*

Dr. Andrea Mairani

Benedikt Kopp

Dr. Julia Bauer

Dr. Emanuel Bahn

Dr. Markus Alber

## **LMU**

Dr. Katia Parodi

Dr. Thomas Tessonier